![]() Edwards Lifesciences Edwards Lifesciences is a provider of patient-focused medical solutions for structural heart disease and critical care monitoring. | ![]() Glaukos Glaukos is an ophthalmic medical technology and pharmaceutical company that develops therapies for treating glaucoma, corneal disorders, and retinal diseases. | ||
Founding Date | Founding Date 2015 | Founding Date 1958 | Founding Date 1998 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations London, GB HQ Dandenong South, AU Wien, AT Markham, CA Bogotá, CO Helsinki, FI Helsinki, FI see more | Locations Irvine, US HQ Macquarie Park, AU Wien, AT Dilbeek, BE São Paulo, BR Mississauga, CA Shanghai, CN see more | Locations Aliso Viejo, US HQ Buenos Aires, AR Heatherton, AU Sao Paulo, BR Richmond Hill, CA San José, CR Wiesbaden, DE see more |
Employees | Employees 2,900 | Employees 15,80020% decrease | Employees 90716% increase |
Valuation ($) | Valuation ($) 2.9 b | Valuation ($) 41.8 b | Valuation ($) 7.6 b |
Financial | |||
Revenue (est.) | Revenue (est.) $1.4b (FY, 2025) | Revenue (est.) $6.1b (FY, 2025) | Revenue (est.) $507.4m (FY, 2025) |
Cost of goods | Cost of goods $448.2m (FY, 2025) | Cost of goods $1.3b (FY, 2025) | Cost of goods $111.8m (FY, 2025) |
Gross profit | Gross profit $939.9m (FY, 2025) | Gross profit $4.7b (FY, 2025) | Gross profit $282.8m (FY, 2025) |
Net income | Net income ($242.5m) (FY, 2025) | Net income $1.1b (FY, 2025) | Net income ($187.7m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 307.2m | Total funding raised $ 115m |

Edwards Lifesciences is a provider of patient-focused medical solutions for structural heart disease and critical care monitoring.
View company
Glaukos is an ophthalmic medical technology and pharmaceutical company that develops therapies for treating glaucoma, corneal disorders, and retinal diseases.
View company